ARS Pharma Reports Q4 2025 Earnings with $72.2 Million Net Product Revenue
ARS Pharma (SPRY) reported net product revenue of $72.2 million for the year, driven by full-year U.S. sales of neffy. Total revenue reached $84.3 million and SG&A expenses were $230.1 million due to commercialization efforts.
Tickers: $SPRY
Topics: cash_position commercial_operations expenses revenue